Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first discovered in Wuhan, China in 2019. The disease it causes (coronavirus disease-19-COVID-19) was officially named on 11 February 2019 by the World Health Organization. At the beginning of May 2020, there are nearly 230 000 cases of COVID-19-related deaths and around 3 267 000 cases confirmed worldwide (WHO: COVID-19 Situation report-103.) The pathophysiology of COVID-19 includes SARS-CoV-2 binding to the alveolar epithelium, thus activating innate immune system and adaptive immune system and resulting in a pro-inflammatory cascade, including the release of

No abstract

BACKGROUNDAspergillosis is a frequent invasive fungal infection in liver recipients (affecting 1%-9.2% of all patients), second only to candidiasis. Significant risk factors for invasive aspergillosis in liver recipients include corticosteroid therapy, neutropenia, T-cell dysfunction, renal failure and requirement for renal replacement therapy. Aspergillus infection usually affects the lungs of liver recipients, with hematogenous dissemination occurring in 50%-60% of cases. Renal involvement is rare and is considered to occur in 0.4% of all cases of invasive aspergillosis.CASE SUMMARYThis paper describes a case of a liver recipient presenting with a newly formed renal mass a year after liver transplantation. The patient underwent liver transplantation due to alcoholic liver cirrhosis, with preoperative corticosteroid therapy and postoperative immunosuppressants (tacrolimus and mycophenolate mofetil). His 1-year follow-up was uneventful, with a satisfying graft function and lack of any symptoms. During a routine follow-up abdominal ultrasound, he was diagnosed with a renal tumor. The renal imaging findings were inconclusive (with a differential diagnosis to renal cell carcinoma), while the computed tomography (CT) of the chest showed scar tissue in the lungs suggestive of previous inflammation. The patient underwent radical nephrectomy, with histopathological analysis showing renal aspergilloma, yielding postoperative treatment with voriconazole. His follow up was uneventful, and the chest CT did not show any change in pulmonary lesions. This case illustrates the possibility of aspergillosis affecting the lungs of liver recipients, subsequently affecting the kidney and forming an aspergilloma.CONCLUSIONClinicians should be aware of aspergilloma mimicking solid organ tumors in organ recipients.

The tensor fasciae latae (TFL) (Folia Morphol 2015; 74, 3: 389-395)

Objective: To present a case of relapsing and resistant Sweet’s syndrome that developed during pregnancy together with an onset of Crohn’s disease, showing complete resolution with the use of infliximab. Clinical Presentation and Intervention: A 30-year-old pregnant woman presented with fever, skin lesions, and diarrhea. Skin biopsy confirmed neutrophilic dermatosis and she was diagnosed with Crohn’s disease after endoscopy. There was no recurrence of Sweet’s syndrome outside of her pregnancy. During a previous pregnancy, while corticosteroids were ineffective, complete regression of skin lesions was achieved using infliximab. Conclusion: The “off-label” use of infliximab is beneficial for relapsing and resistant Sweet’s syndrome.